Acta Neuropathol, 2013 · DOI: 10.1007/s00401-012-1039-8 · Published: September 1, 2012
The blood–brain barrier and blood–spinal cord barrier (BSCB) limit the entry of plasma components and erythrocytes into the central nervous system (CNS). Pericytes play a key role in maintaining blood–CNS barriers. The BSCB is damaged in patients with amyotrophic lateral sclerosis (ALS).
Detection of BSCB disruption and pericyte loss could serve as potential biomarkers for ALS diagnosis or disease progression.
Targeting vascular dysfunction and promoting BSCB integrity and pericyte survival may offer new therapeutic avenues for ALS.
MRI studies in ALS patients should be interpreted with caution due to the small size of spinal cord hemosiderin deposits, which may limit the sensitivity and specificity of conventional T2*-weighted MRI imaging pulse sequences.